Casein hydrolysates (4%) administered to mice with HFD-induced obesity decreased systemic inflammation induced by the HFD and improved ITT (i.e., IR), reduced fasting insulin and HOMA-IR, although FBG was unchanged compared with the HFD group [111]. This evidence concerns the gene INS and obesity disorder.